SCHEMBL25252301

SCHEMBL25252301

Cc1cc(C(F)(F)F)nc(Cl)c1CBr

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
NT5E P21589 1/20 0.35
NPSR1 Q6W5P4 2/20 0.32
KDM4E B2RXH2 4/20 0.32
LMNA P02545 3/20 0.32
HSD17B10 Q99714 2/20 0.31
MEN1 O00255 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP2C19 P33261 2/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
TSHR P16473 1/20 0.30
CRHBP P24387 1/20 0.30
CRHR2 Q13324 1/20 0.30
CYP1A2 P05177 1/20 0.30
FABP4 P15090 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29464842 0.83 HSP90AA1 (0.37) HSP90AA1HSP90AB1NT5ENPSR1KDM4E
SCHEMBL23269465 0.83 HSP90AA1 (0.37) HSP90AA1HSP90AB1NT5ENPSR1KDM4E
SCHEMBL3706754 0.76 KDM4E (0.37) NPSR1KDM4ELMNAMEN1KMT2A
SCHEMBL11985863 0.76 HSP90AA1 (0.42) HSP90AA1HSP90AB1NT5EKDM4ELMNA
SCHEMBL25738942 0.75 HSP90AA1 (0.32) HSP90AA1HSP90AB1NPSR1KDM4ELMNA
SCHEMBL31679112 0.72 CYP19A1 (0.38) KDM4EHSD17B10ALDH1A1TSHR
SCHEMBL25252389 0.72 CYP19A1 (0.38) KDM4EHSD17B10ALDH1A1TSHR
SCHEMBL25289582 0.70 PARP1 (0.33)
SCHEMBL23269422 0.69 HSP90AA1 (0.40) HSP90AA1HSP90AB1KDM4ELMNAHSD17B10
SCHEMBL6217742 0.69 ALDH1A1 (0.61) HSP90AA1HSP90AB1NT5EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 US disclosed
EP-4452984-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Molecure S.A. (PL) 2024-10-30 EP disclosed
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed
WO-2023119233-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-06-29 WO disclosed
WO-2023119233-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF USP7, USP28, USP1 HSP90AA1 2316/4885HSP90AB1 1990/4885NT5E 2585/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 HSP90AA1 2316/4885HSP90AB1 1990/4885NT5E 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.